To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Screening and novel thera… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Screening and novel therapies for retinopathy of prematurity – A review

Journal article
Authors Ann Hellström
Anna-Lena Hård
Published in Early Human Development
Volume 138
ISSN 0378-3782
Publication year 2019
Published at Institute of Neuroscience and Physiology
Language en
Keywords Prediction, Prevention, Retinopathy of prematurity
Subject categories Ophthalmology


© 2019 Elsevier B.V. With current screening for sight threatening retinopathy of prematurity (ROP) <10% of screened infants need treatment. Prediction models based on birth characteristics, postnatal weight gain and other factors have been developed to reduce examinations in low-risk infants. A model based on advanced statistics using data from >7000 infants registered in the Swedish ROP registry is being developed. Based on birth characteristics only, it appears to predict total risk of ROP-treatment as well as models including weight measurements. Treatment risk peaked at 12 weeks of age. Laser therapy is the method of choice for severe ROP. Anti-VEGF therapies are implemented worldwide despite insufficient knowledge of choice of drug, dosage and long term systemic effects. Prevention of ROP may be achieved through oxygen control and provision of the mother's breastmilk. Other interventions such as supplementation with long chain polyunsaturated fatty acids and preservation of fetal haemoglobin are investigated.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?